Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of MK-2870 versus treatment of physician's choice as second-line therapy for recurrent or metastatic cervical cancer
CTR20243424Phase 3Active
- Sponsor
- MSD
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in Cervical Cancer (CC), sponsored by MSD. Started Feb 2025; status: active.
02
Drugs
sacituzumab tirumotecan
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20243424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243424.